Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
Clinical and translational advances in ovarian cancer therapy
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
Applications of patient-derived tumor xenograft models and tumor organoids
GJ Yoshida - Journal of hematology & oncology, 2020 - Springer
Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
[HTML][HTML] ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …
Precision medicine: disease subty** and tailored treatment
Simple Summary The genomics-based concept of precision medicine began to emerge
following the completion of the Human Genome Project. In contrast to evidence-based …
following the completion of the Human Genome Project. In contrast to evidence-based …